---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-100156"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:12:01.949200+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q3 prelim rev >$100M, raises FY25 pro forma guidance to at least $375M

## Summary
- Q3 2025 preliminary net revenue >$100M; DefenCath revenue >$85M; pro forma net revenue >$125M.
- FY25 pro forma net revenue guidance raised from $325-350M to at least $375M.
- Q3 adjusted EBITDA expected at least $70M; ~$30M cost synergies on run-rate basis by year-end.
- Phase III ReSPECT study of Rezzayo fully enrolled; data expected 2Q 2026.
- Cash and equivalents ~$56M at Sep 30; projected year-end cash ~$100M.

## SEC filing metadata
- accession: 0001213900-25-100156
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/0001213900-25-100156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/ea0261760-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-100156
- JSON: https://secwatch.observer/filing/0001213900-25-100156.json
- Plain text: https://secwatch.observer/filing/0001213900-25-100156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.